Avera Cancer Sequencing and Analytics Protocol (ASAP)
Key facts
- Where
- Aberdeen, Marshall, Mitchell, Pierre, Sioux Falls, and Yankton, United StatesSee the 6 sites
Where in United States
- Avera Cancer Institute-AberdeenAberdeen, United StatesTaking people
- Avera Cancer Institute - MarshallMarshall, United StatesTaking people
- Avera Cancer Institute - MitchellMitchell, United StatesTaking people
- Avera Cancer Institute - PierrePierre, United StatesTaking people
- Avera Cancer InstituteSioux Falls, United StatesTaking people
- Avera Cancer Institute - YanktonYankton, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Avera McKennan Hospital & University Health Center
- Trial code
- NCT05142033
- Record updated
- 28 October 2026
- Original description
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.Read full original descriptionShow less
Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.
Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.
To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.
Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.
Inclusion: Must be at least 18 years of age; Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer; Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation.
Exclusion: Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements; Participants incapable of understanding the items listed in the consent form and process.